A recent meta-analysis attempted to address this issue quantitatively.[8] Unfortunately, that meta-analysis neglected several studies, especially those correlating overexpression of HER-2 with a favorable prognosis for osteosarcoma and utilized a less robust technique by not taking time to an event into account when calculating outcome estimates.[10] As there is no general consensus about the impact and significance of HER-2 status on survival and whether the effect is consistent among different subgroups, clinical use of HER-2 in osteosarcoma remains limited. This evidence concerns the gene ERBB2 and osteosarcoma.